Revvity is seeing mild pressure today, mirroring a broader downward trend across the diagnostics and research industry as peers like Thermo Fisher Scientific, Waters Corporation, and Mettler-Toledo International are also trading lower.
While the company recently garnered attention for the launch of its CE-IVDR-certified GSP T1D 3plex kit for type 1 diabetes screening, this news has not been enough to decouple the stock from the wider sector weakness. The recent filing of a Form 144 on September 27 serves as a reminder of the stock's significant 78% r